Genentech pulls breast cancer drug after FDA questions accelerated approval

Amid a closer look by regulators at cancer drugs given accelerated approval, Genentech Inc. voluntarily withdrew a multibillion-dollar drug for a type of breast cancer. The South San Francisco-based U.S. biotech unit of Swiss drug giant Roche made the decision regarding the drug, known scientifically as atezolizumab and...

Click to view original post